Prevention of recurrent miscarriage in women with antiphospholipid syndrome: A systematic review and network meta-analysis

Abstract

Objectives

To compare and rank currently available pharmacological interventions for the prevention of recurrent miscarriage (RM) in women with antiphospholipid syndrome (APS).

Methods

A search was performed using PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, CNKI, ClinicalTrials.gov, and the UK National Research Register on December 15, 2019. Studies comparing any types of active interventions with placebo/inactive control or another active intervention for the prevention of RM in patients with APS were considered for inclusion. The primary outcomes were efficacy (measured by live birth rate) and acceptability (measured by all-cause discontinuation); secondary outcomes were birthweight, preterm birth, preeclampsia, and intrauterine growth retardation. The protocol of this study was registered with Open Science Framework (DOI: 10.17605/OSF.IO/B9T4E).

Results

In total, 54 randomized controlled trials (RCTs) comprising 4,957 participants were included. Low-molecular-weight heparin (LMWH) alone, aspirin plus LMWH or unfractionated heparin (UFH), aspirin plus LMWH plus intravenous immunoglobulin (IVIG), aspirin plus LMWH plus IVIG plus prednisone were found to be effective pharmacological interventions for increasing live birth rate (ORs ranging between 2.88 to 11.24). In terms of acceptability, no significant difference was found between treatments. In terms of adverse perinatal outcomes, aspirin alone was associated with a higher risk of preterm birth than aspirin plus LMWH (OR 3.92, 95% CI 1.16 to 16.44) and with lower birthweight than LMWH (SMD −808.76, 95% CI −1596.54 to −5.07).

Conclusions

Our findings support the use of low-dose aspirin plus heparin as the first-line treatment for prevention of RM in women with APS, and support the efficacy of hydroxychloroquine, IVIG, and prednisone when added to current treatment regimens. More large-scale, high-quality RCTs are needed to confirm these findings, and new pharmacological options should be further evaluated.

Keywords

Antiphospholipid syndrome recurrent miscarriage pregnancy systematic review network meta-analysis

Get full access to this article

View all access options for this article.

References

Ruiz-Irastorza

Crowther

Branch

Khamashta

MA.

Antiphospholipid syndrome. Lancet 2010; 376: 1498–1509.

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Schreiber

Hunt

BJ.

Pregnancy and antiphospholipid syndrome. Semin Thromb Hemost 2016; 42: 780–788.

Cervera

Serrano

Pons-Estel

, et al.; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74: 1011–1018.

Mekinian

Costedoat-Chalumeau

Masseau

, et al.

Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?

Autoimmun Rev 2015; 14: 23–29.

Pierangeli

Chen

González

EB.

Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006; 13: 366–375.

Di Simone

Meroni

de Papa

, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43: 140–150.

Schreiber

Radin

Sciascia

Current insights in obstetric antiphospholipid syndrome. Curr Opin Obstet Gynecol 2017; 29: 397–403.

Comarmond

Cacoub

Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 2013; 12: 752–757.

10.

De Carolis

Tabacco

Rizzo

, et al. Antiphospholipid syndrome: an update on risk factors for pregnancy outcome. Autoimmun Rev 2018; 17: 956–966.

11.

Espinosa

Cervera

Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 2015; 11: 586–596.

12.

Bouvier

Cochery-Nouvellon

Lavigne-Lissalde

, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123: 404–413.

13.

Cowchock

Reece

Balaban

Branch

Plouffe

Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166: 1318–1323.

14.

Jiao

Pang

Aspirin, low-molecule-weight heparin, and prednisone in treating recurrent miscarriage associated with antiphospholipid syndrome. China Pract Med 2019; 14: 130–132.

15.

Liu

The effectiveness of aspirin plus prednisone in treating recurrent miscarriage associated with antiphospholipid syndrome. Electron J Pract Gynecol Endocrinol 2019; 6: 33–37.

16.

Chen

Treatments for recurrent miscarriage associated with antiphospholipid syndrome. Medical Diet Health 2019; 11: 1–3.

17.

Dendrinos

Sakkas

Makrakis

Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 2009; 104: 223–225.

18.

Empson

Lassere

Craig

Scott

Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005; 2005: Cd002859.

19.

Mekinian

Lazzaroni

Kuzenko

, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015; 14: 498–502.

20.

Lazzaroni

M-G

Fredi

Andreoli

, et al. Triple antiphospholipid (aPL) antibodies positivity is associated with pregnancy complications in aPL carriers: a multicenter study on 62 pregnancies. Front Immunol 2019; 10: 1948–1948.

21.

Saccone

Berghella

Maruotti

, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol 2017; 216: 525.e521. e512.

22.

Laskin

Spitzer

Clark

, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol 2009; 36: 279–287.

23.

Khalid

Enoxaparin and aspirin therapy for recurrent pregnancy loss due to anti-phospholipid syndrome (APS). Middle East Fertil Soc J 2014; 19: 176–182.

24.

Aspirin and low molecular heparin in prevention of recurrent pregnancy loss associated with antiphospholipid syndrome. J Pract Gynecol Endocrinol (Electronic Edition) 2018; 5: 53–54.

25.

Farquharson

Quenby

Greaves

Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408–413.

26.

Tang

Aspirin plus low-molecular weight heparin or prednisone in treating miscarriage associated with antiphospholipid syndrome. Chinese J Human Sex 2014; 18: 12–13.

27.

Zhang

Wang

Ding

Aspirin and low molecular heparin in treating recurrent miscarriage caused by antiphospholipid syndrome. Hebei Med 2018; 24: 422–426.

28.

Ziakas

Pavlou

Voulgarelis

Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010; 115: 1256–1262.

29.

Mak

Cheung

Cheak

RC.

Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010; 49: 281–288.

30.

Liu

Jiang

HL.

Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med 2019; 32: 1299–1311.

31.

Hutton

Salanti

Caldwell

, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777–784.

32.

Higgins

JPT

Altman

Gøtzsche

, et al.; Cochrane Statistical Methods Group. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. Bmj 2011; 343: d5928.

33.

Olkin

Dahabreh

Trikalinos

TA.

GOSH – a graphical display of study heterogeneity. Res Synth Methods 2012; 3: 214–223.

34.

Deng

Pan

Lin

Observation of treatment effectiveness on 50 cases of obstetrical antiphospholipid syndrome. J Gannan Med Univ 2012; 32: 374–375.

35.

Merli

Groce

JB.

Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P & T: 2010; 35: 95–105.

36.

Devis

Knuttinen

MG.

Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management. Cardiovasc Diagn Therapy 2017; 7: S309–S319.

37.

Andreoli

Bertsias

Agmon-Levin

, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76: 476–485.

38.

Ismail

Hamed

Saso

Abu-Elhasan

Abu-Elghar

Abdelmeged

AN.

Randomized controlled study of pre-conception thromboprophylaxis among patients with recurrent spontaneous abortion related to antiphospholipid syndrome. Int J Gynaecol Obstet 2016; 132: 219–223.

39.

Perino

Vassiliadis

Vucetich

, et al. Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod 1997; 12: 2388–2392.

40.

Rai

Regan

Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 1354.

41.

Schreiber

Breen

Cohen

, et al. HYdroxychloroquine to improve pregnancy outcome in women with antiphospholipid antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017; 43: 562–571.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

2.90 MB